[1]
|
Teo, Z.L., Tham, Y.C., Yu, M., et al. (2021) Global Prevalence of Diabetic Retinopathy and Projection of Burden through 2045: Systematic Review and Meta-Analysis. Ophthalmology, 128, 1580-1591. https://doi.org/10.1016/j.ophtha.2021.04.027
|
[2]
|
Ting, D.S., Cheung, G.C. and Wong, T.Y. (2016) Diabetic Retinopathy: Global Prevalence, Major Risk Factors, Screening Practices and Public Health Challenges: A Review. Clinical & Experimental Ophthalmology, 44, 260-277. https://doi.org/10.1111/ceo.12696
|
[3]
|
Tan, G.S., Cheung, N., Sim, R., et al. (2017) Diabetic Macular Oedema. The Lancet Diabetes & Endocrinology, 5, 143-155. https://doi.org/10.1016/S2213-8587(16)30052-3
|
[4]
|
Bressler, S.B., Ayala, A.R., Bressler, N.M., et al. (2016) Persistent Macular Thickening after Ranibizumab Treatment for Diabetic Macular Edema with Vision Impairment. JAMA Ophthalmology, 134, 278-285. https://doi.org/10.1001/jamaophthalmol.2015.5346
|
[5]
|
Janssen, E.M., Dy, S.M., Meara, A.S., et al. (2020) Analysis of Patient Preferences in Lung Cancer—Estimating Acceptable Tradeoffs between Treatment Benefit and Side Effects. Patient Preference and Adherence, 14, 927-937. https://doi.org/10.2147/PPA.S235430
|
[6]
|
Schmidt-Erfurth, U., Garcia-Arumi, J., Bandello, F., et al. (2017) Guidelines for the Management of Diabetic Macular Edema by the European Society of Retina Specialists (EURETINA). Ophthalmologica, 237, 185-222. https://doi.org/10.1159/000458539
|
[7]
|
Sim, R., Sundstrom, J.M. and Antonetti, D.A. (2014) Ocular Anti-VEGF Therapy for Diabetic Retinopathy: The Role of VEGF in the Pathogenesis of Diabetic Retinopathy. Diabetes Care, 37, 893-899. https://doi.org/10.2337/dc13-2002
|
[8]
|
Blick, S.K., Keating, G.M. and Wagstaff, A.J. (2007) Ranibizumab. Drugs, 67, 1199-1206. https://doi.org/10.2165/00003495-200767080-00007
|
[9]
|
Papadopoulos, N., Martin, J., Ruan, Q., et al. (2012) Binding and Neutralization of Vascular Endothelial Growth Factor (VEGF) and Related Ligands by VEGF Trap, Ranibizumab and Bevacizumab. Angiogenesis, 15, 171-185. https://doi.org/10.1007/s10456-011-9249-6
|
[10]
|
Gaudreault, J., Fei, D., Beyer, J.C., et al. (2007) Pharmacokinetics and Retinal Distribution of Ranibizumab, A Humanized Antibody Fragment Directed against VEGF-A, following Intravitreal Administration in Rabbits. Retina, 27, 1260-1266. https://doi.org/10.1097/IAE.0b013e318134eecd
|
[11]
|
Nguyen, Q.D., Brown, D.M., Marcus, D.M., et al. (2012) Ranibizumab for Diabetic Macular Edema: Results from 2 Phase III Randomized Trials: RISE and RIDE. Ophthalmology, 119, 789-801. https://doi.org/10.1016/j.ophtha.2011.12.039
|
[12]
|
Mitchell, P., Bandello, F., Schmidt-Erfurth, U., et al. (2011) The RESTORE Study: Ranibizumab Monotherapy or Combined with Laser versus Laser Monotherapy for Diabetic Macular Edema. Ophthalmology, 118, 615-625. https://doi.org/10.1016/j.ophtha.2011.01.031
|
[13]
|
Ishibashi, T., Li, X., Koh, A., et al. (2015) The REVEAL Study: Ranibizumab Monotherapy or Combined with Laser versus Laser Monotherapy in Asian Patients with Diabetic Macular Edema. Ophthalmology, 122, 1402-1415. https://doi.org/10.1016/j.ophtha.2015.02.006
|
[14]
|
Pearce, I., Banerjee, S., Burton, B.J., et al. (2015) Ranibizumab 0.5 Mg for Diabetic Macular Edema with Bimonthly Monitoring after a Phase of Initial Treatment: 18-Month, Multicenter, Phase IIIB RELIGHT Study. Ophthalmology, 122, 1811-1819. https://doi.org/10.1016/j.ophtha.2015.05.038
|
[15]
|
Elman, M.J., Ayala, A., Bressler, N.M., et al. (2015) Intravitreal Ranibizumab for Diabetic Macular Edema with Prompt versus Deferred Laser Treatment: 5-Year Randomized Trial Results. Ophthalmology, 122, 375-381. https://doi.org/10.1016/j.ophtha.2014.08.047
|
[16]
|
Schmidt-Erfurth, U., Lang, G.E., Holz, F.G., et al. (2014) Three-Year Outcomes of Individualized Ranibizumab Treatment in Patients with Diabetic Macular Edema: The RESTORE Extension Study. Ophthalmology, 121, 1045-1053. https://doi.org/10.1016/j.ophtha.2013.11.041
|
[17]
|
Srinivas, S., Verma, A., Nittala, M.G., et al. (2020) Effect of Intravitreal Ranibizumab on Intraretinal Hard Exudates in Eyes with Diabetic Macular Edema. American Journal of Ophthalmology, 211, 183-190. https://doi.org/10.1016/j.ajo.2019.11.014
|
[18]
|
Chatziralli, I., Theodossiadis, G., Dimitriou, E., et al. (2020) Association between the Patterns of Diabetic Macular Edema and Photoreceptors’ Response after Intravitreal Ranibizumab Treatment: A Spectral-Domain Optical Coherence Tomography Study. International Ophthalmology, 40, 2441-2448. https://doi.org/10.1007/s10792-020-01423-3
|
[19]
|
Mori, Y., Suzuma, K., Uji, A., et al. (2016) Restoration of Foveal Photoreceptors after Intravitreal Ranibizumab Injections for Diabetic Macular Edema. Scientific Reports, 6, Article No. 39161. https://doi.org/10.1038/srep39161
|
[20]
|
Yigit, K., Inan, ü., Inan, S., et al. (2021) Long-Term Full-Field and Multifocal Electroretinographic Changes after Treatment with Ranibizumab in Patients with Diabetic Macular Edema. International Ophthalmology, 41, 1487-1501. https://doi.org/10.1007/s10792-021-01712-5
|
[21]
|
Comyn, O., Sivaprasad, S., Peto, T., et al. (2014) A Randomized Trial to Assess Functional and Structural Effects of Ranibizumab versus Laser in Diabetic Macular Edema (The LUCIDATE Study). American Journal of Ophthalmology, 157, 960-970. https://doi.org/10.1016/j.ajo.2014.02.019
|
[22]
|
Zarbin, M.A., Dunger-Baldauf, C., Haskova, Z., et al. (2017) Vascular Safety of Ranibizumab in Patients with Diabetic Macular Edema: A Pooled Analysis of Patient-Level Data from Randomized Clinical Trials. JAMA Ophthalmology, 135, 424-431. https://doi.org/10.1001/jamaophthalmol.2017.0455
|
[23]
|
Brown, D.M., Emanuelli, A., Bandello, F., et al. (2022) KESTREL and KITE: 52-Week Results from Two Phase III Pivotal Trials of Brolucizumab for Diabetic Macular Edema. American Journal of Ophthalmology, 238, 157-172. https://doi.org/10.1016/j.ajo.2022.01.004
|
[24]
|
Wykoff, C.C., Garweg, J.G., Regillo, C., et al. (2023) KESTREL and KITE Phase 3 Studies: 100-Week Results with Brolucizumab in Patients with Diabetic Macular Edema. American Journal of Ophthalmology, 260, 70-83. https://doi.org/10.1016/j.ajo.2023.07.012
|
[25]
|
Singh, R.P., Barakat, M.R., Ip, M.S., et al. (2023) Efficacy and Safety of Brolucizumab for Diabetic Macular Edema: The KINGFISHER Randomized Clinical Trial. JAMA Ophthalmology, 141, 1152-1160. https://doi.org/10.1001/jamaophthalmol.2023.5248
|
[26]
|
Abu Serhan, H., Taha, M.J.J., Abuawwad, M.T., et al. (2023) Safety and Efficacy of Brolucizumab in the Treatment of Diabetic Macular Edema and Diabetic Retinopathy: A Systematic Review and Meta-Analysis. Seminars in Ophthalmology. https://doi.org/10.1080/08820538.2023.2271095
|
[27]
|
Hirano, T., Kumazaki, A., Tomihara, R., et al. (2023) Evaluating Initial Responses to Brolucizumab in Patients Undergoing Conventional Anti-VEGF Therapy for Diabetic Macular Edema: A Retrospective, Single-Center, Observational Study. Scientific Reports, 13, Article No. 10901. https://doi.org/10.1038/s41598-023-37726-5
|
[28]
|
Heier, J.S., Korobelnik, J.F., Brown, D. M., et al. (2016) Intravitreal Aflibercept for Diabetic Macular Edema: 148-Week Results from the VISTA and VIVID Studies. Ophthalmology, 123, 2376-2385. https://doi.org/10.1016/j.ophtha.2016.07.032
|
[29]
|
Dhoot, D.S., Moini, H., Reed, K., et al. (2023) Functional Outcomes of Sustained Improvement on Diabetic Retinopathy Severity Scale with Intravitreal Aflibercept in the VISTA and VIVID Trials. Eye, 37, 2020-2025. https://doi.org/10.1038/s41433-022-02058-7
|
[30]
|
Chen, Y.X., Li, X.X., Yoon, Y.H., et al. (2020) Intravitreal Aflibercept versus Laser Photocoagulation in Asian Patients with Diabetic Macular Edema: The VIVID-East Study. Clinical Ophthalmology, 14, 741-750. https://doi.org/10.2147/OPTH.S235267
|
[31]
|
Wang, X., He, X., Qi, F., et al. (2022) Different Anti-Vascular Endothelial Growth Factor for Patients with Diabetic Macular Edema: A Network Meta-Analysis. Frontiers in Pharmacology, 13, Article 876386. https://doi.org/10.3389/fphar.2022.876386
|
[32]
|
Xie, X., Lian, C., Zhang, Z., et al. (2023) Aflibercept for Long-Term Treatment of Diabetic Macular Edema and Proliferative Diabetic Retinopathy: A Meta-Analysis. Frontiers in Endocrinology, 14, Article 1144422. https://doi.org/10.3389/fendo.2023.1144422
|
[33]
|
Bhandari, S., Nguyen, V., Fraser-Bell, S., et al. (2020) Ranibizumab or Aflibercept for Diabetic Macular Edema: Comparison of 1-Year Outcomes from the Fight Retinal Blindness! Registry. Ophthalmology, 127, 608-615. https://doi.org/10.1016/j.ophtha.2019.11.018
|
[34]
|
Sarda, V., Eymard, P., Hrarat, L., et al. (2020) Comparison of the Effect of Ranibizumab and Aflibercept on Changes in Macular Choroidal Thickness in Patients Treated for Diabetic Macular Edema. Journal of Ophthalmology, 2020, Article ID: 5708354. https://doi.org/10.1155/2020/5708354
|
[35]
|
Moradian, S., Soheilian, M., Asadi, M., et al. (2023) Ziv-Aflibercept in Diabetic Macular Edema: Relation of Subfoveal Choroidal Thickness with Visual and Anatomical Outcomes. Journal of Ophthalmic & Vision Research, 18, 164-169. https://doi.org/10.18502/jovr.v18i2.13182
|
[36]
|
BAYER (2023) Aflibercept 8 Mg in Diabetic Macular Edema First to Achieve Sustained Vision Gains with up to 83% of Patients Extended to 16-24 Weeks at Two Years. https://www.bayer.com/media/en-us/aflibercept-8-mg-in-diabetic-macular-edema-first-to-achieve-sustained-vision-gains-with-up-to-83-of-patients-extended-to--16-24-weeks-at-two-years/
|
[37]
|
Wu, Z., Zhou, P., Li, X., et al. (2013) Structural Characterization of a Recombinant Fusion Protein by Instrumental Analysis and Molecular Modeling. PLOS ONE, 8, e57642. https://doi.org/10.1371/journal.pone.0057642
|
[38]
|
Liu, K., Wang, H., He, W., et al. (2022) Intravitreal Conbercept for Diabetic Macular Oedema: 2-Year Results from a Randomised Controlled Trial and Open-Label Extension Study. The British Journal of Ophthalmology, 106, 1436-1443. https://doi.org/10.1136/bjophthalmol-2020-318690
|
[39]
|
Sun, X., Zhang, J., Tian, J., et al. (2020) Comparison of the Efficacy and Safety of Intravitreal Conbercept with Intravitreal Ranibizumab for Treatment of Diabetic Macular Edema: A Meta-Analysis. Journal of Ophthalmology, 2020, Article ID: 5809081. https://doi.org/10.1155/2020/5809081
|
[40]
|
Cui, Z., Zhou, W., Chang, Q., et al. (2021) Cost-Effectiveness of Conbercept vs. Ranibizumab for Age-Related Macular Degeneration, Diabetic Macular Edema, and Pathological Myopia: Population-Based Cohort Study and Markov Model. Frontiers in Medicine, 8, Article 750132. https://doi.org/10.3389/fmed.2021.750132
|
[41]
|
Nicol, M., Ferro, Desideri, L., Vagge, A., et al. (2021) Faricimab: An Investigational Agent Targeting the Tie-2/Angiopoietin Pathway and VEGF-A for the Treatment of Retinal Diseases. Expert Opinion on Investigational Drugs, 30, 193-200. https://doi.org/10.1080/13543784.2021.1879791
|
[42]
|
Sahni, J., Patel, S.S., Dugel, P.U., et al. (2019) Simultaneous Inhibition of Angiopoietin-2 and Vascular Endothelial Growth Factor-A with Faricimab in Diabetic Macular Edema: BOULEVARD Phase 2 Randomized Trial. Ophthalmology, 126, 1155-1170. https://doi.org/10.1016/j.ophtha.2019.03.023
|
[43]
|
Wykoff, C.C., Abreu, F., Adamis, A.P., et al. (2022) Efficacy, Durability, and Safety of Intravitreal Faricimab with Extended Dosing up to Every 16 Weeks in Patients with Diabetic Macular Oedema (YOSEMITE and RHINE): Two Randomised, Double- Masked, Phase 3 Trials. Lancet, 399, 741-755. https://doi.org/10.1016/S0140-6736(22)00018-6
|
[44]
|
Takamura, Y., Yamada, Y., Morioka, M., et al. (2023) Turnover of Microaneurysms after Intravitreal Injections of Faricimab for Diabetic Macular Edema. Investigative Ophthalmology & Visual Science, 64, Article 31. https://doi.org/10.1167/iovs.64.13.31
|
[45]
|
Yamada, Y., Takamura, Y., Morioka, M., et al. (2021) Microaneurysm Density in Residual Oedema after Anti-Vascular Endothelial Growth Factor Therapy for Diabetic Macular Oedema. Acta Ophthalmologica, 99, e876-e883. https://doi.org/10.1111/aos.14706
|
[46]
|
Ohara, H., Harada, Y., Hiyama, T., et al. (2023) Faricimab for Diabetic Macular Edema in Patients Refractory to Ranibizumab or Aflibercept. Medicina, 59, Article 1125. https://doi.org/10.3390/medicina59061125
|
[47]
|
Romero-Aroca, P., Baget-Bernaldiz, M., Pareja-Rios, A., et al. (2016) Diabetic Macular Edema Pathophysiology: Vasogenic versus Inflammatory. Journal of Diabetes Research, 2016, Article ID: 2156273. https://doi.org/10.1155/2016/2156273
|
[48]
|
Noma, H., Yasuda, K. and Shimura, M. (2021) Involvement of Cytokines in the Pathogenesis of Diabetic Macular Edema. International Journal of Molecular Sciences, 22, Article 3427. https://doi.org/10.3390/ijms22073427
|
[49]
|
Zhang, J., Zhang, J., Zhang, C., et al. (2022) Diabetic Macular Edema: Current Understanding, Molecular Mechanisms and Therapeutic Implications. Cells, 11, Article 3362. https://doi.org/10.3390/cells11213362
|
[50]
|
Mesquida, M., Drawnel, F. and Fauser, S. (2019) The Role of Inflammation in Diabetic Eye Disease. Seminars in Immunopathology, 41, 427-445. https://doi.org/10.1007/s00281-019-00750-7
|
[51]
|
Lai, D., Wu, Y., Shao, C. and Qu, Q.H. (2023) The Role of Müller Cells in Diabetic Macular Edema. Investigative Ophthalmology & Visual Science, 64, Article 8. https://doi.org/10.1167/iovs.64.10.8
|
[52]
|
Zur, D., Iglicki, M. and Loewenstein, A. (2019) The Role of Steroids in the Management of Diabetic Macular Edema. Ophthalmic Research, 62, 231-236. https://doi.org/10.1159/000499540
|
[53]
|
Himasa, F.I., Singhal, M., Ojha, A., et al. (2022) Prospective for Diagnosis and Treatment of Diabetic Retinopathy. Current Pharmaceutical Design, 28, 560-569. https://doi.org/10.2174/1381612827666211115154907
|
[54]
|
Tang, L., Xu, G.T. and Zhang, J.F. (2023) Inflammation in Diabetic Retinopathy: Possible Roles in Pathogenesis and Potential Implications for Therapy. Neural Regeneration Research, 18, 976-982. https://doi.org/10.4103/1673-5374.355743
|
[55]
|
Imai, S., Otsuka, T., Naito, A., et al. (2017) Triamcinolone Acetonide Suppresses Inflammation and Facilitates Vascular Barrier Function in Human Retinal Microvascular Endothelial Cells. Current Neurovascular Research, 14, 232-241. https://doi.org/10.2174/1567202614666170619081929
|
[56]
|
Zajac-Pytrus, H.M., Kaczmarek, R., StronSka-Lipowicz, D., et al. (2017) The Effects and Safety of Intravitreal Triamcinolone Injections in the Treatment of Diabetic Macular Edema. Advances in Clinical and Experimental Medicine, 26, 45-49. https://doi.org/10.17219/acem/29849
|
[57]
|
Kato, F., Nozaki, M., Kato, A., et al. (2023) Retinal Microvascular Changes after Intravitreal Triamcinolone Acetonide in Diabetic Macular Edema. Journal of Clinical Medicine, 12, Article 3475. https://doi.org/10.3390/jcm12103475
|
[58]
|
Ibrahim, M.H., Salman, A.G., Said, A.M., et al. (2021) Efficacy of Posterior Sub- Tenon’s Capsule Injection Compared to Intravitreal Injection of Triamcinolone Acetonide for Treatment of Diabetic Macular Edema: A Systematic Review and Meta-Analysis. QJM: An International Journal of Medicine, 114, hcab109.019. https://doi.org/10.1093/qjmed/hcab109.019
|
[59]
|
Tomita, Y., Lee, D., Tsubota, K., et al. (2021) Updates on the Current Treatments for Diabetic Retinopathy and Possibility of Future Oral Therapy. Journal of Clinical Medicine, 10, Article 4666. https://doi.org/10.3390/jcm10204666
|
[60]
|
Chiu, C.Y., Huang, T.L., Chang, P.Y., et al. (2021) Combined Intravitreal Ranibizumab and Posterior Subtenon Triamcinolone Acetonide Injections for Patients with Diabetic Macular Edema Refractory to Intravitreal Ranibizumab Monotherapy. Taiwan Journal of Ophthalmology, 11, 251-258. https://doi.org/10.4103/tjo.tjo_31_20
|
[61]
|
Maturi, R.K., Glassman, A.R., Liu, D., et al. (2018) Effect of Adding Dexamethasone to Continued Ranibizumab Treatment in Patients with Persistent Diabetic Macular Edema: A DRCR Network Phase 2 Randomized Clinical Trial. JAMA Ophthalmology, 136, 29-38. https://doi.org/10.1001/jamaophthalmol.2017.4914
|
[62]
|
Maturi, R.K., Pollack, A., Uy, H.S., et al. (2016) Intraocular Pressure in Patients with Diabetic Macular Edema Treated with Dexamethasone Intravitreal Implant in the 3-Year Mead Study. Retina, 36, 1143-1152. https://doi.org/10.1097/IAE.0000000000001004
|
[63]
|
Zarranz-Ventura, J., Sala-Puigdollers, A., Velazquez-Villoria, D., et al. (2019) Long- Term Probability of Intraocular Pressure Elevation with the Intravitreal Dexamethasone Implant in the Real-World. PLOS ONE, 14, e0209997. https://doi.org/10.1371/journal.pone.0209997
|
[64]
|
Boyer, D.S., Yoon, Y.H., Belfort Jr., R., et al. (2014) Three-Year, Randomized, Sham- Controlled Trial of Dexamethasone Intravitreal Implant in Patients with Diabetic Macular Edema. Ophthalmology, 121, 1904-1914. https://doi.org/10.1016/j.ophtha.2014.04.024
|
[65]
|
Chi, S.C., Kang, Y.N. and Huang, Y.M. (2023) Efficacy and Safety Profile of Intravitreal Dexamethasone Implant versus Antivascular Endothelial Growth Factor Treatment in Diabetic Macular Edema: A Systematic Review and Meta-Analysis. Scientific Reports, 13, Article No. 7428. https://doi.org/10.1038/s41598-023-34673-z
|
[66]
|
Mitchell, P., Arnold, J., Fraser-Bell, S., et al. (2023) Dexamethasone Intravitreal Implant in Diabetic Macular Oedema Refractory to Anti-Vascular Endothelial Growth Factors: The AUSSIEDEX Study. BMJ Open Ophthalmology, 8, e001224. https://doi.org/10.1136/bmjophth-2022-001224
|
[67]
|
Nicol, M., Musetti, D., Marenco, M., et al. (2020) Real-Life Management of Diabetic Macular Edema with Dexamethasone Intravitreal Implant: A Retrospective Analysis of Long-Term Clinical Outcomes. Journal of Ophthalmology, 2020, Article ID: 4860743. https://doi.org/10.1155/2020/4860743
|
[68]
|
Rosenblatt, A., Udaondo, P., Cunha-Vaz, J., et al. (2020) A Collaborative Retrospective Study on the Efficacy and Safety of Intravitreal Dexamethasone Implant (Ozurdex) in Patients with Diabetic Macular Edema: The European DME Registry Study. Ophthalmology, 127, 377-393. https://doi.org/10.1016/j.ophtha.2019.10.005
|
[69]
|
Ruiz-Moreno, J.M., Adán, A., Lafuente, M., et al. (2023) Effectiveness and Safety of Fluocinolone Acetonide Intravitreal Implant in Diabetic Macular Edema Patients Considered Insufficiently Responsive to Available Therapies (REACT): A Prospective, Non-Randomized, and Multicenter Study. International Ophthalmology, 43, 4639-4649. https://doi.org/10.1007/s10792-023-02864-2
|
[70]
|
Veritti, D., Sarao, V., Diplotti, L., et al. (2017) Fluocinolone Acetonide for the Treatment of Diabetic Macular Edema. Expert Opinion on Pharmacotherapy, 18, 1507- 1516. https://doi.org/10.1080/14656566.2017.1363182
|
[71]
|
Campochiaro, P.A., Hafiz, G., Shah, S.M., et al. (2010) Sustained Ocular Delivery of Fluocinolone Acetonide by an Intravitreal Insert. Ophthalmology, 117, 1393-1399.E3. https://doi.org/10.1016/j.ophtha.2009.11.024
|
[72]
|
Eaton, A., Koh, S.S., Jimenez, J. and Riemann, C.D. (2019) The USER Study: A Chart Review of Patients Receiving A 0.2μG/Day Fluocinolone Acetonide Implant for Diabetic Macular Edema. Ophthalmology and Therapy, 8, 51-62. https://doi.org/10.1007/s40123-018-0155-5
|
[73]
|
Singer, M.A., Sheth, V., Mansour, S.E., et al. (2022) Three-Year Safety and Efficacy of the 0.19-Mg Fluocinolone Acetonide Intravitreal Implant for Diabetic Macular Edema: The PALADIN Study. Ophthalmology, 129, 605-613. https://doi.org/10.1016/j.ophtha.2022.01.015
|
[74]
|
Rousseau, N., Lebreton, O., Masse, H., et al. (2023) Fluocinolone Acetonide Implant Injected 1 Month after Dexamethasone Implant for Diabetic Macular Oedema: The ILUVI1MOIS Study. Ophthalmology and Therapy, 12, 2781-2792. https://doi.org/10.1007/s40123-023-00749-2
|
[75]
|
Leite, J., Ferreira, A., Castro, C., et al. (2023) Retinal Changes after Fluocinolone Acetonide Implant (ILUVIEN®) for DME: SD-OCT Imaging Assessment Using ESASO Classification. European Journal of Ophthalmology, 34, 233-244. https://doi.org/10.1177/11206721231183471
|
[76]
|
Kodjikian, L., Bandello, F., De Smet, M., et al. (2022) Fluocinolone Acetonide Implant in Diabetic Macular Edema: International Experts’ Panel Consensus Guidelines and Treatment Algorithm. European Journal of Ophthalmology, 32, 1890-1899. https://doi.org/10.1177/11206721221080288
|
[77]
|
Campochiaro, P.A., Brown, D.M., Pearson, A., et al. (2011) Long-Term Benefit of Sustained-Delivery Fluocinolone Acetonide Vitreous Inserts for Diabetic Macular Edema. Ophthalmology, 118, 626-635.E2. https://doi.org/10.1016/j.ophtha.2010.12.028
|
[78]
|
Chakravarthy, U., Taylor, S.R., Koch, F.H.J., et al. (2019) Changes in Intraocular Pressure after Intravitreal Fluocinolone Acetonide (ILUVIEN): Real-World Experience in Three European Countries. The British Journal of Ophthalmology, 103, 1072-1077. https://doi.org/10.1136/bjophthalmol-2018-312284
|
[79]
|
Nozaki, M., Ando, R., Kimura, T., et al. (2023) The Role of Laser Photocoagulation in Treating Diabetic Macular Edema in the Era of Intravitreal Drug Administration: A Descriptive Review. Medicina, 59, Article 1319. https://doi.org/10.3390/medicina59071319
|
[80]
|
Callanan, D.G., Gupta, S., Boyer, D.S., et al. (2013) Dexamethasone Intravitreal Implant in Combination with Laser Photocoagulation for the Treatment of Diffuse Diabetic Macular Edema. Ophthalmology, 120, 1843-1851. https://doi.org/10.1016/j.ophtha.2013.02.018
|
[81]
|
Nguyen, Q.D., Shah, S.M., Khwaja, A.A., et al. (2010) Two-Year Outcomes of the Ranibizumab for Edema of the mAcula in Diabetes (READ-2) Study. Ophthalmology, 117, 2146-2151. https://doi.org/10.1016/j.ophtha.2010.08.016
|
[82]
|
Sejournet, L., Kodjikian, L., Elbany, S., et al. (2023) Focal Photocoagulation as an Adjunctive Therapy to Reduce the Burden of Intravitreal Injections in Macula Edema Patients, the LyoMAC2 Study. Pharmaceutics, 15, Article 308. https://doi.org/10.3390/pharmaceutics15020308
|
[83]
|
Tamura, K., Yokoyama, T., Ebihara, N., et al. (2012) Histopathologic Analysis of the Internal Limiting Membrane Surgically Peeled from Eyes with Diffuse Diabetic Macular Edema. Japanese Journal of Ophthalmology, 56, 280-287. https://doi.org/10.1007/s10384-012-0130-y
|
[84]
|
Bonnin, S., Sandali, O., Bonnel, S., et al. (2015) Vitrectomy with Internal Limiting Membrane Peeling for Tractional and Nontractional Diabetic Macular Edema: Long-Term Results of a Comparative Study. Retina, 35, 921-928. https://doi.org/10.1097/IAE.0000000000000433
|
[85]
|
Ivastinovic, D., Haas, A., Weger, M., et al. (2021) Vitrectomy for Diabetic Macular Edema and the Relevance of External Limiting Membrane. BMC Ophthalmology, 21, Article No. 334. https://doi.org/10.1186/s12886-021-02095-y
|
[86]
|
Rinaldi, M., Dell’omo, R., Morescalchi, F., et al. (2018) ILM Peeling in Nontractional Diabetic Macular Edema: Review and Metanalysis. International Ophthalmology, 38, 2709-2714. https://doi.org/10.1007/s10792-017-0761-6
|
[87]
|
Ranno, S., Vujosevic, S., Mambretti, M., et al. (2023) Role of Vitrectomy in Nontractional Refractory Diabetic Macular Edema. Journal of Clinical Medicine, 12, Article 2297. https://doi.org/10.3390/jcm12062297
|
[88]
|
Guo, H., Li, W., Nie, Z., et al. (2023) Microinvasive Pars Plana Vitrectomy Combined with Internal Limiting Membrane Peeling versus Anti-VEGF Intravitreal Injection for Treatment-Naive Diabetic Macular Edema (VVV-DME Study): Study Protocol for A Randomized Controlled Trial. Trials, 24, Article No. 685. https://doi.org/10.1186/s13063-023-07735-w
|